Interactive essay / educational decision support
Finding the right antidepressant is less about finding a "magic pill" and more about finding a biological fit for your life. Depression can emerge from interacting systems: mood regulation, stress, sleep, inflammation, cognition, and lived context. This essay shows how a decision interface can make tradeoffs visible.
Educational only. This page supports a clinical conversation. Diagnosis, medication starts, stops, and treatment decisions need a licensed clinician. If you may harm yourself or someone else in the U.S., call or text 988.
Shift the question
We look at your symptoms, your "deal-breaker" side effects, and how quickly you need relief to find your best starting point.
Why it matters
Medication is personal. Two people might have the same depression, but one prioritizes sleep while the other needs to avoid weight gain. There is no wrong priority. About 40% to 60% of people notice a significant improvement in their symptoms with the first antidepressant they try. If the first one does not work, fit logic helps make the next choice more deliberate.
What to do with it
Use the movement and ranking to name target symptoms, priorities, and side-effect tradeoffs for a clinician conversation. Treat it as a question generator rather than a chooser.
Not every side effect is an emergency. We'll help you distinguish between annoying effects that go away and deal-breakers that mean we should pivot.
AskWhich side effects are common, which are urgent, and when should I message you?
TrackTrack sleep, stomach symptoms, feeling wired/jittery, sedation, sexual function, appetite, and anything rapidly worsening.
Choose any non-negotiables first. The shortlist will move around those boundaries before comparing medications.
Sertraline / SSRI
A common go-to for both depression and anxiety. It's highly effective, though we'll want to watch for an upset stomach in the first week.
All medication nodes still stay visible in the landscape; this shortlist keeps the comparison focused.
Bupropion / NDRI
Often used for energy and motivation. It has a lower risk of sexual side effects but can occasionally feel too wired for people with high anxiety.
First couple weeks
Early side effects, sleep shifts, feeling wired/jittery, or GI changes can appear before mood benefit is clear.
Mirtazapine / NaSSA
A sleep-and-appetite supporting profile that may fit insomnia or low appetite but can conflict with weight or daytime sedation concerns.
First couple weeks
Early side effects, sleep shifts, feeling wired/jittery, or GI changes can appear before mood benefit is clear.
Duloxetine / SNRI
An SNRI profile that may be considered when mood, anxiety, energy, or pain-related context overlaps.
First couple weeks
Early side effects, sleep shifts, feeling wired/jittery, or GI changes can appear before mood benefit is clear.
Make uncertainty visible
The bands below are educational likelihood ranges and uncertainty markers. They serve as population-level teaching ranges and leave out some possible adverse effects.
Why it matters
Side effects are rarely all-or-nothing labels. Ranges keep uncertainty visible and prevent a clean-looking option from seeming risk-free.
What to do with it
Compare the burdens you most care about, then turn the widest or highest-concern bands into monitoring questions for the first few weeks.
A common go-to for both depression and anxiety. It's highly effective, though we'll want to watch for an upset stomach in the first week.
Early side effects, sleep shifts, feeling wired/jittery, or GI changes can appear before mood benefit is clear.
Parallel levers
Therapy, sleep regularity, movement, and light exposure influence overlapping systems. The dashboard offers a directional illustration instead of an efficacy calculator.
Why it matters
Medication response is shaped by the surrounding system. A poor match, disrupted sleep, or lack of sunlight can pull the trajectory down even when another lever is helping.
What to do with it
Track one or two modifiable levers alongside medication response so a partial trial is not interpreted in isolation from sleep, routines, light, or therapy.
After the first trial
Once a medication has been tried, the useful question becomes what the observed response means: stable benefit, partial movement, no signal, or a tolerability problem.
Why it matters
After a trial starts, observed response and tolerability matter more than pre-trial fit. Benefit, partial movement, no signal, and side effects lead to different questions.
What to do with it
Pick the closest response state and use the playbook to prepare a focused follow-up conversation before changing, stopping, adding, or increasing anything.
Sertraline / SSRI
nausea can appear early / sexual side effects may matter
Decision frame
The signal is unclear, so the next step is separating incomplete benefit from a mismatched target.
Review duration, dose history, missed doses, early improvement, and side effects before interpreting the trial.
Therapy, sleep regularity, movement, and light exposure may shift the response without changing the core medication.
Switching changes the core profile; augmentation adds a second track and can increase interaction and side-effect burden.
Time-based trial tracker
Benefits and side effects often emerge on different timelines. A compact log can make the next conversation more concrete without turning the page into a medical record.
Why it matters
Follow-up visits often depend on memory, and memory compresses good weeks, bad weeks, missed doses, side effects, and context changes.
What to do with it
Log just enough to compare weeks, then bring the generated summary as a structured prompt for the next clinician conversation.
Baseline symptoms, side-effect priorities, safety flags, and follow-up plan.
Early side effects and wired/jittery or sedation patterns may be clearer than benefit.
Early improvement can be informative, and early non-improvement can still change over time.
Response, tolerability, taking it consistently, and measurement usually guide the next category of decision.
Maintenance, relapse prevention, and taper questions are revisited with the clinician.
No logs yet.
Sources
These links are included for source transparency. The page functions as an educational tool prototype rather than a clinical decision tool.
Why it matters
The source trail makes the prototype auditable and separates educational reasoning from hidden authority.
What to do with it
Use the links to inspect the assumptions behind the tool and to anchor questions for professional review.
Shared decision-making, treatment review, limited-response pathways, and monitoring.
Measurement-based care and staged management of major depressive disorder.
Personalized, collaborative management with attention to preferences and tolerability.
CBT, second-generation antidepressants, and combination approaches as evidence-based options.
Dose-dependent QT prolongation warning and cardiac-risk cautions for citalopram.
Contraindications and seizure-risk cautions for bupropion products.
Esketamine indications, REMS monitoring, blood pressure, sedation, dissociation, and abuse/misuse cautions.
FDA psychiatric approval applies to esketamine nasal spray; compounded at-home ketamine products carry monitoring and safety concerns.
Pregnancy and postpartum treatment decisions require individualized risk-benefit review.
Bipolar assessment and management pathways differ from unipolar depression pathways.
Anxiety symptoms change treatment goals and tolerability conversations.
PTSD medication evidence and the central role of trauma-focused psychotherapy.
Early symptom change can inform later outcome expectations while leaving room for later changes.
U.S. call, text, or chat crisis support through 988.